Patent classifications
C07K16/02
Anti-ICOS antibodies
Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
Coated egg yolk cores, methods of making and methods of use thereof
A method of making coated avian egg yolk cores includes providing dried avian egg yolk cores having a diameter of 100 to 1500 micrometers, applying avian egg albumen to the dried avian egg yolk cores to provide the coated avian egg yolk cores, and optionally drying the coated avian egg yolk cores, wherein the ratio of dry avian egg albumen to dried avian egg yolk in the coated avian egg yolk cores is 1:10 to 10:1. Also included are the coated avian egg yolk cores, food and feed additives containing the coated avian egg yolk cores and food and feed compositions containing the coated avian egg yolk cores.
Coated egg yolk cores, methods of making and methods of use thereof
A method of making coated avian egg yolk cores includes providing dried avian egg yolk cores having a diameter of 100 to 1500 micrometers, applying avian egg albumen to the dried avian egg yolk cores to provide the coated avian egg yolk cores, and optionally drying the coated avian egg yolk cores, wherein the ratio of dry avian egg albumen to dried avian egg yolk in the coated avian egg yolk cores is 1:10 to 10:1. Also included are the coated avian egg yolk cores, food and feed additives containing the coated avian egg yolk cores and food and feed compositions containing the coated avian egg yolk cores.
GIARDIA RECOMBINANT ANTIGENS, PURIFICATION OF POLYCLONAL ANTI-GIARDIA IGG AND IGY ANTIBODIES AND GIARDIA DETECTION
The present invention relates to a stationary phase for the purification of polyclonal anti-Giardia IgG and IgY antibodies, as well as a method for purifying polyclonal anti-Giardia IgG and IgY antibodies by affinity chromatography. The invention also relates to the polyclonal anti-Giardia IgG and IgY antibodies purified by affinity chromatography, which specifically bind to the antigenic proteins CWP1, alpha-giardin 7.3 and kinesin 3.
In an additional aspect, the invention relates to a method for diagnosing giardiasis by detection of Giardia in a specific sample, and a kit for diagnosing giardiasis in biological and environmental samples.
GIARDIA RECOMBINANT ANTIGENS, PURIFICATION OF POLYCLONAL ANTI-GIARDIA IGG AND IGY ANTIBODIES AND GIARDIA DETECTION
The present invention relates to a stationary phase for the purification of polyclonal anti-Giardia IgG and IgY antibodies, as well as a method for purifying polyclonal anti-Giardia IgG and IgY antibodies by affinity chromatography. The invention also relates to the polyclonal anti-Giardia IgG and IgY antibodies purified by affinity chromatography, which specifically bind to the antigenic proteins CWP1, alpha-giardin 7.3 and kinesin 3.
In an additional aspect, the invention relates to a method for diagnosing giardiasis by detection of Giardia in a specific sample, and a kit for diagnosing giardiasis in biological and environmental samples.
Antibody specifically binding to FOLR1 and uses thereof
A modified antibody that binds specifically to folate receptor alpha (FOLR1) and blocks the activity of FOLR1 with an increased binding affinity, an antigen-binding fragment thereof, a composition containing the antibody or fragment, and their uses are disclosed. The modified antibody or antigen-binding fragment thereof may be used for the prevention or treatment of cancer proliferative disorder associated with an increased FOR1 expression, and may also be used for diagnosis of the disease. The proliferative disorder may be cancer.
Antibody specifically binding to FOLR1 and uses thereof
A modified antibody that binds specifically to folate receptor alpha (FOLR1) and blocks the activity of FOLR1 with an increased binding affinity, an antigen-binding fragment thereof, a composition containing the antibody or fragment, and their uses are disclosed. The modified antibody or antigen-binding fragment thereof may be used for the prevention or treatment of cancer proliferative disorder associated with an increased FOR1 expression, and may also be used for diagnosis of the disease. The proliferative disorder may be cancer.
Compositions and methods for reducing methane producing bacteria in animals
Compositions for reducing the emission of methane by ruminant animals are disclosed. The compositions include avian antibodies against methanogens generally found in the rumen of the animals. Egg contents of eggs from female birds inoculated with immunogenic compositions containing one or more methanogens or antigens derived from methanogens are used. The antibodies in the egg contents may be used directly without further purification, may be partially purified or purified. The compositions may be administered in drinking water or in animal feed. Administering of the anti-methanogenic composition reduces the emission of methane and increases the efficiency of feed conversion.
Compositions and methods for reducing methane producing bacteria in animals
Compositions for reducing the emission of methane by ruminant animals are disclosed. The compositions include avian antibodies against methanogens generally found in the rumen of the animals. Egg contents of eggs from female birds inoculated with immunogenic compositions containing one or more methanogens or antigens derived from methanogens are used. The antibodies in the egg contents may be used directly without further purification, may be partially purified or purified. The compositions may be administered in drinking water or in animal feed. Administering of the anti-methanogenic composition reduces the emission of methane and increases the efficiency of feed conversion.
Composition and Methods for Treating Acute Diarrhea and Enteric
The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.